Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A dispersible tablet comprising Compound I of the formula



or a pharmaceutically acceptable salt thereof present in an amount of from 5% to 40% in weight based on the total weight of the tablet and at least one disintegrant in a total amount of 10% to 35% in weight based on the total weight of the tablet.

Claims 2 and 3 (canceled)

Claim 4 (previously presented): The dispersible tablet according to claim 1, wherein Compound I is in the free acid form.

Claim 5 (previously presented): The dispersible tablet according to claim 1 wherein Compound I is in a crystalline form.

Claim 6 (previously presented): The dispersible tablet according to claim 1 wherein a lubricant is present in less than 1% in weight based on the total weight of the tablet.

Claim 7 (original): The dispersible tablet according to claim 6 wherein the lubricant is present in less than 0.4% in weight based on the total weight of the tablet.

Claim 8 (canceled)

Claim 9 (currently amended): The dispersible tablet according to claim ~~8~~ 1 wherein the disintegration time of the tablet is of 3 minutes or less.

Claim 10 (currently amended): The dispersible tablet according to claim ~~2~~ 1 wherein the pharmaceutically acceptable excipients comprise:

(i) at least one filler in a total amount of about 35 to 55 % in weight based on the total weight of the tablet,

~~(ii) at least one disintegrant in a total amount of about 10% to 35% in weight based on the total weight of the tablet~~

~~(iii)~~ (ii) at least one binder in a total amount of about 1.5% to 5% in weight based on the total weight of the tablet,

~~(iv)~~ (iii) at least one surfactant in a total amount of about 0.2% to 1% in weight based on the total weight of the tablet,

~~(v)~~ (iv) at least one glidant in a total amount of about 0.1% to 0.5% in weight based on the total weight of the tablet, and/or

~~(vi)~~ (v) at least one lubricant in a total amount of less than about 0.4% in weight based on the total weight of the tablet.

Claim 11 (previously presented): The dispersible tablet according to claim 10 wherein the lubricant is magnesium stearate.

Claim 12 (previously presented): The dispersible tablet according to claim 10 containing Compound I in its free acid form in an amount of about 100 mg to 600 mg .

Claim 13 (currently amended): A method of treating a patient suffering from iron overload comprising administering to ~~a mammal~~ the patient in need of such a treatment a daily dose of 5 to 40 mg/kg of body weight of Compound I as an active ingredient.

Claim 14 (currently amended): A process for the preparation of the dispersible tablet according to claim ~~10~~ 1, which comprises:

(i) mixing the Compound I or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient;

(ii) wet-granulating the mixture obtained in (i);

(iii) mixing the granulates obtained in (ii) with at least one pharmaceutically acceptable excipient to form a mixture; and

(iv) spraying the lubricant on the materials contacting surfaces of pressing tools of the tabletting machine and compressing the mixture obtained in step (iii) to form a tablet.

Claim 15 (original): The process according to claim 14 wherein the lubricant is magnesium stearate.

Claims 16 through 21(canceled)

Claim 22 (new): The dispersible tablet according to claim 1 wherein the Compound I is present in an amount of 25% to 40% in weight based on the total weight of the tablet.

Claim 23 (new): The dispersible tablet according to claim 22 wherein the Compound I is present in an amount of 28% to 32% in weight based on the total weight of the tablet.

Claim 24 (new): The dispersible tablet according to claim 1 comprising an iron-chelating pharmacologically effective amount of compound I or a pharmaceutically acceptable salt thereof.